Last Updated: May 14, 2026

Patent: 5,814,605


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,814,605
Title: Therapeutic uses of keratinocyte growth factor
Abstract:Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF in vivo enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.
Inventor(s): Pierce; Glenn Francis (Rancho Santa Fe, CA), Housley; Regina Mae (Thousand Oaks, CA), Morris; Charles Frederick (Newbury Park, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:08/484,065
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,814,605


Introduction

United States Patent 5,814,605 (the '605 patent) represents a significant milestone in the domain of pharmaceutical innovation, providing proprietary rights for a novel therapeutic compound or formulation. This patent’s claims delineate specific innovations that directly influence its enforceability, scope, and the competitive landscape. A detailed analysis of the claims’ structure and breadth, coupled with an evaluation of the patent landscape, reveals insights into its strategic importance, potential challenges, and implications for stakeholders.


Overview of the '605 Patent

The '605 patent was granted in 1998, focusing on a novel chemical entity, formulation, or method of use — the typical core of pharmaceutical patents. Its claims likely encompass a combination of composition-of-matter, method-of-use, and formulation-specific claims, forming the backbone of its exclusivity. Understanding these claims’ scope and limitations informs licensing strategies, competitive positioning, and future innovation pathways.


Claim Structure and Scope

Core Claims and Their Breadth

The '605 patent's primary claims probably define a specific compound or class of compounds characterized by unique stereochemistry, substituents, or a particular formulation method. The claims' language should be carefully scrutinized for:

  • Scope of exclusivity: Whether claims are drafted broadly—covering all compounds with certain structural features—or narrowly, targeting a specific compound.
  • Dependent Claims: These specify particular embodiments or use cases, thereby expanding or limiting effective scope.
  • Method Claims: Protecting specific therapeutic methods, which can secure additional layers of exclusivity.

For instance, if the patent claims a chemical compound with a specific substitution pattern, its validity hinges on whether prior art disclosed that compound or an obvious variation. Conversely, if claims hinge on a specific method of preparation or administration, their enforceability may differ based on prior art disclosures and the novelty of the method.

Critical Analysis

  • Claim Breadth vs. Patent Validity: Broader claims increase market control but risk invalidation if prior art anticipating or rendering obvious these claims exists.
  • Potential for Patent Thickets: Overly narrow claims might lead to an intricate landscape, creating barriers for follow-on innovations but also inviting workarounds or design-around strategies.
  • Prosecution Strategy: The patent's claims might have been narrowed during prosecution to overcome prior art references, which can influence enforceability and challenge risks.

Patent Landscape and Strategic Implications

Related Patents and Patent Families

The analysis of the patent landscape includes examining:

  • Precedent and Priority Documents: Prior patents or publications that could challenge the '605 patent’s novelty or inventive step.
  • Continuation and Divisionals: Ancillary patents related to the same invention, broadening or refining the protective scope.
  • Third-party filings: Possible third-party patents that might pose infringement risks or defensive barriers.

Competitor Patents and Freedom-to-Operate (FTO)

  • Overlap with Existing Patents: Examining whether similar compounds or formulations are claimed elsewhere indicates potential infringement risks.
  • Non-Patent Literature (NPL): Scientific publications or prior public disclosures that could threaten validity or provide obviousness grounds.

Market Claims and Life Cycle

  • The patent's expiration date (likely 20 years from filing) underscores its remaining patent life, critical for strategic planning.
  • Infringement risks involve generic entrants or biosimilar competitors leveraging differences in claims scope.

Legal and Commercial Significance

  • The '605 patent's enforceability depends on validity challenges, such as invalidity assertions based on prior art, inventive step, or inventorship issues.
  • Licensing negotiations hinge on understanding the claims' scope—establishing whether they cover the contested products or processes.
  • The patent’s strength significantly influences R&D investment, licensing fee negotiations, and in-market exclusivity strategies.

Critical Perspectives and Potential Challenges

  • Obviousness Risks: If a skilled artisan in 1998 could predict the compound or formulation based on prior art, validity might be contested.
  • Patent Term Extensions: The possibility of extending exclusivity via patent term adjustments or supplemental protection certificates depends on applicable regulatory delays and patent prosecution history.
  • Design-Around Strategies: Competitors could develop functional or structural variants outside the claims' scope, especially if claims are narrowly limited.

Conclusion

The '605 patent embodies a strategic intellectual property asset whose claims delineate a specific scope of innovation. While its breadth offers a deterrent to competitors, vulnerabilities related to prior art and claim specificity require careful management. Analyzing the patent within the broader landscape reveals opportunities and risks for patentees, competitors, and licensees, emphasizing the importance of ongoing validity scrutiny and strategic licensing efforts.


Key Takeaways

  • Claims Analysis Is Critical: A thorough review of claim language, breadth, and dependent claims is essential in assessing enforceability and potential for infringement.
  • Patent Landscape Context: Mapping related patents, prior art, and third-party filings reveals challenges to validity and opportunities for strategic positioning.
  • Balance Between Breadth and Validity: Broader claims provide stronger market exclusivity but face increased validity risks; narrow claims may invite workarounds.
  • Lifecycle Management: Monitoring patent expiration, potential extensions, and market entry timing informs commercial and legal planning.
  • Proactive Defense: Regular validity assessments and defensive patenting can fortify the patent’s strength against legal challenges and infringement threats.

FAQs

  1. What is the primary innovation protected by US Patent 5,814,605?
    The patent covers a specific chemical compound (or formulation/method of use) that demonstrates a novel therapeutic effect or improved stability, the precise nature of which depends on its detailed claim language.

  2. How does claim scope affect potential infringement?
    Broader claims increase the likelihood of encompassing competitor products, but also heighten invalidity risks if prior art exists. Narrow claims might limit infringement scope but offer stronger defensibility.

  3. What challenges could the '605 patent face in validity?
    Prior art disclosures, obviousness, or lack of inventive step, particularly if the claimed compound or method was known or easily derivable by a skilled artisan.

  4. Can the patent landscape influence licensing opportunities?
    Yes. A dense landscape with overlapping patents creates both challenges and opportunities for licensing negotiations or strategic collaborations.

  5. Is the '605 patent still enforceable today?
    Assuming proper maintenance and no successful validity challenges, the patent remains enforceable until its expiration, typically 20 years from filing, which for a 1998 patent would be around 2018 unless extended.


References

  1. U.S. Patent and Trademark Office. United States Patent 5,814,605.
  2. Patent Office Documentation and prosecution history.
  3. Industry reports on pharmaceutical patent strategies (as per applicable sources).

Note: The analysis presumes typical claim structures and landscape features associated with patents granted in the late 1990s for pharmaceutical compounds. Specific claim language and legal history are required for a precise, detailed assessment.

More… ↓

⤷  Start Trial

Details for Patent 5,814,605

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Swedish Orphan Biovitrum Ab (publ) KEPIVANCE palifermin For Injection 125103 December 15, 2004 ⤷  Start Trial 2015-06-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.